Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
Abstract Background/aim We assessed suitable factors indicating newly developed lenvatinib (LEN) treatment for unresectable hepatocellular carcinoma (u‐HCC) by investigating real‐world clinical features of patients. Materials/methods One hundred fifty two u‐HCC patients, who receive LEN treatment fr...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-07-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.2241 |
id |
doaj-cccc682807da4c209ad4c989c8c9c14b |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Atsushi Hiraoka Takashi Kumada Masanori Atsukawa Masashi Hirooka Kunihiko Tsuji Toru Ishikawa Koichi Takaguchi Kazuya Kariyama Ei Itobayashi Kazuto Tajiri Noritomo Shimada Hiroshi Shibata Hironori Ochi Toshifumi Tada Hidenori Toyoda Kazuhiro Nouso Akemi Tsutsui Takuya Nagano Norio Itokawa Korenobu Hayama Michitaka Imai Kouji Joko Yohei Koizumi Yoichi Hiasa Kojiro Michitaka Masatoshi Kudo the Real‐life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) |
spellingShingle |
Atsushi Hiraoka Takashi Kumada Masanori Atsukawa Masashi Hirooka Kunihiko Tsuji Toru Ishikawa Koichi Takaguchi Kazuya Kariyama Ei Itobayashi Kazuto Tajiri Noritomo Shimada Hiroshi Shibata Hironori Ochi Toshifumi Tada Hidenori Toyoda Kazuhiro Nouso Akemi Tsutsui Takuya Nagano Norio Itokawa Korenobu Hayama Michitaka Imai Kouji Joko Yohei Koizumi Yoichi Hiasa Kojiro Michitaka Masatoshi Kudo the Real‐life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis Cancer Medicine adverse event hand‐foot skin reaction hepatic function hepatocellular carcinoma lenvatinib modified albumin‐bilirubin grade |
author_facet |
Atsushi Hiraoka Takashi Kumada Masanori Atsukawa Masashi Hirooka Kunihiko Tsuji Toru Ishikawa Koichi Takaguchi Kazuya Kariyama Ei Itobayashi Kazuto Tajiri Noritomo Shimada Hiroshi Shibata Hironori Ochi Toshifumi Tada Hidenori Toyoda Kazuhiro Nouso Akemi Tsutsui Takuya Nagano Norio Itokawa Korenobu Hayama Michitaka Imai Kouji Joko Yohei Koizumi Yoichi Hiasa Kojiro Michitaka Masatoshi Kudo the Real‐life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) |
author_sort |
Atsushi Hiraoka |
title |
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis |
title_short |
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis |
title_full |
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis |
title_fullStr |
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis |
title_full_unstemmed |
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis |
title_sort |
prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—multicenter analysis |
publisher |
Wiley |
series |
Cancer Medicine |
issn |
2045-7634 |
publishDate |
2019-07-01 |
description |
Abstract Background/aim We assessed suitable factors indicating newly developed lenvatinib (LEN) treatment for unresectable hepatocellular carcinoma (u‐HCC) by investigating real‐world clinical features of patients. Materials/methods One hundred fifty two u‐HCC patients, who receive LEN treatment from March to December 2018, were enrolled. (Child‐Pugh score [CPS] 5/6/7/8 = 76/61/13/2, modified albumin‐bilirubin grade [mALBI] 1/2a/2b/3 = 53/35/60/4). Clinical features were evaluated retrospectively. Results Overall‐response rate (ORR)/disease control rate (DCR) at 1 month after starting LEN were 38.7%/86.0%, respectively. Estimated median time to progression (TTP) was 7.0 months, while median survival time was not reached within the observation period. CPS (≥7) and past history of tyrosine‐kinase inhibitor (TKI) were not significant prognostic factors. mALBI ≥2b was an only significant prognostic factor (HR 4.632, 95%CI 1.649‐13.02, P = 0.004) in Cox‐hazard multivariate analysis. In patients with Child‐Pugh A, c‐index/Akaike's information criterion (AIC) of prognostic predictive value of mALBI were superior to CPS (0.682/135.6 vs 0.652/138.7), while those of stopping LEN also showed that mALBI was better (0.575/447.3 vs 0.562/447.8). Additional analysis of patients with good mALBI (1/2a) revealed that time to stopping LEN was significantly shorter in those with the adverse event (AE) of appetite loss (any grade) than those without (P = 0.006) and body mass index (BMI) was also lower in patients with that AE (20.3 ± 3.0 vs 23.6 ± 4.0kg/m2, P < 0.001), while patients with a hand‐foot skin reaction (any grade) showed good ORR/DCR (59.1%/86.4%) and longer TTP as compared to patients without (P = 0.007). Conclusion Good hepatic function (mALBI 1/2a) is the best indication for LEN, while potential appetite loss in association with low BMI should be kept in mind in such cases. |
topic |
adverse event hand‐foot skin reaction hepatic function hepatocellular carcinoma lenvatinib modified albumin‐bilirubin grade |
url |
https://doi.org/10.1002/cam4.2241 |
work_keys_str_mv |
AT atsushihiraoka prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT takashikumada prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT masanoriatsukawa prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT masashihirooka prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT kunihikotsuji prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT toruishikawa prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT koichitakaguchi prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT kazuyakariyama prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT eiitobayashi prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT kazutotajiri prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT noritomoshimada prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT hiroshishibata prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT hironoriochi prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT toshifumitada prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT hidenoritoyoda prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT kazuhironouso prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT akemitsutsui prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT takuyanagano prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT norioitokawa prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT korenobuhayama prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT michitakaimai prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT koujijoko prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT yoheikoizumi prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT yoichihiasa prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT kojiromichitaka prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT masatoshikudo prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis AT thereallifepracticeexpertsforhccrelpecstudygrouphcc48grouphepatocellularcarcinomaexpertsfrom48clinicsinjapan prognosticfactoroflenvatinibforunresectablehepatocellularcarcinomainrealworldconditionsmulticenteranalysis |
_version_ |
1725279897683755008 |
spelling |
doaj-cccc682807da4c209ad4c989c8c9c14b2020-11-25T00:43:12ZengWileyCancer Medicine2045-76342019-07-01883719372810.1002/cam4.2241Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysisAtsushi Hiraoka0Takashi Kumada1Masanori Atsukawa2Masashi Hirooka3Kunihiko Tsuji4Toru Ishikawa5Koichi Takaguchi6Kazuya Kariyama7Ei Itobayashi8Kazuto Tajiri9Noritomo Shimada10Hiroshi Shibata11Hironori Ochi12Toshifumi Tada13Hidenori Toyoda14Kazuhiro Nouso15Akemi Tsutsui16Takuya Nagano17Norio Itokawa18Korenobu Hayama19Michitaka Imai20Kouji Joko21Yohei Koizumi22Yoichi Hiasa23Kojiro Michitaka24Masatoshi Kudo25the Real‐life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)Gastroenterology Center Ehime Prefectural Central Hospital Ehime JapanDepartment of Gastroenterology and Hepatology Ogaki Municipal Hospital Gifu JapanDivision of Gastroenterology and Hepatology, Department of Internal Medicine Nippon Medical School Tokyo JapanDepartment of Gastroenterology and Metabology Ehime University Graduate School of Medicine Ehime JapanCenter of Gastroenterology Teine Keijinkai Hospital Sapporo JapanDepartment of Gastroenterology Saiseikai Niigata Daini Hospital Niigata JapanDepartment of Gastroenterology Okayama City Hospital Okayama JapanDepartment of Hepatology Kagawa Prefectural Central Hospital Takamatsu JapanDepartment of Gastroenterology Asahi General Hospital Asahi JapanDepartment of Gastroenterology Toyama University Hospital Toyama JapanDivision of Gastroenterology and Hepatology Otakanomori Hospital Kashiwa JapanDepartment of Gastroenterology Tokushima Prefectural Central Hospital Tokushima JapanHepato‐biliary Center Matsuyama Red Cross Hospital Matsuyama JapanDepartment of Gastroenterology and Hepatology Ogaki Municipal Hospital Gifu JapanDepartment of Gastroenterology and Hepatology Ogaki Municipal Hospital Gifu JapanDepartment of Hepatology Kagawa Prefectural Central Hospital Takamatsu JapanDepartment of Gastroenterology Okayama City Hospital Okayama JapanDepartment of Gastroenterology Okayama City Hospital Okayama JapanCenter of Gastroenterology Teine Keijinkai Hospital Sapporo JapanCenter of Gastroenterology Teine Keijinkai Hospital Sapporo JapanDepartment of Gastroenterology Saiseikai Niigata Daini Hospital Niigata JapanHepato‐biliary Center Matsuyama Red Cross Hospital Matsuyama JapanDepartment of Gastroenterology and Metabology Ehime University Graduate School of Medicine Ehime JapanDepartment of Gastroenterology and Metabology Ehime University Graduate School of Medicine Ehime JapanGastroenterology Center Ehime Prefectural Central Hospital Ehime JapanFaculty of Medicine, Department of Gastroenterology and Hepatology Kindai University Osaka JapanAbstract Background/aim We assessed suitable factors indicating newly developed lenvatinib (LEN) treatment for unresectable hepatocellular carcinoma (u‐HCC) by investigating real‐world clinical features of patients. Materials/methods One hundred fifty two u‐HCC patients, who receive LEN treatment from March to December 2018, were enrolled. (Child‐Pugh score [CPS] 5/6/7/8 = 76/61/13/2, modified albumin‐bilirubin grade [mALBI] 1/2a/2b/3 = 53/35/60/4). Clinical features were evaluated retrospectively. Results Overall‐response rate (ORR)/disease control rate (DCR) at 1 month after starting LEN were 38.7%/86.0%, respectively. Estimated median time to progression (TTP) was 7.0 months, while median survival time was not reached within the observation period. CPS (≥7) and past history of tyrosine‐kinase inhibitor (TKI) were not significant prognostic factors. mALBI ≥2b was an only significant prognostic factor (HR 4.632, 95%CI 1.649‐13.02, P = 0.004) in Cox‐hazard multivariate analysis. In patients with Child‐Pugh A, c‐index/Akaike's information criterion (AIC) of prognostic predictive value of mALBI were superior to CPS (0.682/135.6 vs 0.652/138.7), while those of stopping LEN also showed that mALBI was better (0.575/447.3 vs 0.562/447.8). Additional analysis of patients with good mALBI (1/2a) revealed that time to stopping LEN was significantly shorter in those with the adverse event (AE) of appetite loss (any grade) than those without (P = 0.006) and body mass index (BMI) was also lower in patients with that AE (20.3 ± 3.0 vs 23.6 ± 4.0kg/m2, P < 0.001), while patients with a hand‐foot skin reaction (any grade) showed good ORR/DCR (59.1%/86.4%) and longer TTP as compared to patients without (P = 0.007). Conclusion Good hepatic function (mALBI 1/2a) is the best indication for LEN, while potential appetite loss in association with low BMI should be kept in mind in such cases.https://doi.org/10.1002/cam4.2241adverse eventhand‐foot skin reactionhepatic functionhepatocellular carcinomalenvatinibmodified albumin‐bilirubin grade |